U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Zoetis

Market Cap: US$31.6b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

Insmed

Market Cap: US$24.2b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Summit Therapeutics

Market Cap: US$12.4b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Praxis Precision Medicines

Market Cap: US$8.7b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Vaxcyte

Market Cap: US$8.2b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

Legend Biotech

Market Cap: US$5.4b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Caris Life Sciences

Market Cap: US$5.0b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Oruka Therapeutics

Market Cap: US$5.0b

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Viking Therapeutics

Market Cap: US$4.5b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Structure Therapeutics

Market Cap: US$3.9b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

Dyne Therapeutics

Market Cap: US$3.8b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

Kailera Therapeutics

Market Cap: US$3.0b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Vera Therapeutics

Market Cap: US$2.9b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

uniQure

Market Cap: US$2.8b

Develops treatments for patients suffering from rare and other devastating diseases in the United States.

BioCryst Pharmaceuticals

Market Cap: US$2.6b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Mineralys Therapeutics

Market Cap: US$2.6b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

Intellia Therapeutics

Market Cap: US$2.5b

Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Nektar Therapeutics

Market Cap: US$2.5b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Kodiak Sciences

Market Cap: US$2.3b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Ocular Therapeutix

Market Cap: US$2.3b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Generate Biomedicines

Market Cap: US$2.2b

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.

Zai Lab

Market Cap: US$2.1b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

ADMA Biologics

Market Cap: US$2.1b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Recursion Pharmaceuticals

Market Cap: US$2.1b

A clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.

Viridian Therapeutics

Market Cap: US$2.1b

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Palvella Therapeutics

Market Cap: US$2.1b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Taysha Gene Therapies

Market Cap: US$2.0b

A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.

Precigen

Market Cap: US$2.0b

A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Syndax Pharmaceuticals

Market Cap: US$2.0b

A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Nuvation Bio

Market Cap: US$1.9b

A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.

Iovance Biotherapeutics

Market Cap: US$1.9b

A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.

Tyra Biosciences

Market Cap: US$1.8b

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

AtaiBeckley

Market Cap: US$1.8b

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

Bausch Health Companies

Market Cap: US$1.8b

Operates as a diversified specialty pharmaceutical and medical device company.

Maze Therapeutics

Market Cap: US$1.8b

A clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.

COMPASS Pathways

Market Cap: US$1.7b

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.